EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dementia and Alzheimer's Disease Associated With Aromatase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database ( VigiBase )

María Teresa Yuste iD, María Sainz-Gil iD, Elisa Escudero iD, Pedro Marín iD

Pharmacology Research & Perspectives · 2025

DOI: 10.1002/prp2.70075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von María Teresa Yuste und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Murcia, Murcia, Spain. Hauptthemen laut MEDLINE: Aromatase Inhibitors, Alzheimer Disease, Dementia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aromatase inhibitors are used for patients with hormone‐receptor positive breast cancer. Alzheimer's disease is the most prevalent cause of dementia. Several studies have suggested an association between the use of aromatase inhibitors and the development of Alzheimer's disease. The objective of this study was to identify potential pharmacovigilance signals associated with dementia and Alzheimer's disease and third‐generation aromatase inhibitors in menopausal and postmenopausal women. VigiBase, the global database of individual case safety reports of the World Health Organization, was used to investigate this possible association. A disproportionality analysis was performed for women aged 45 years and older. The reporting odds ratio (ROR) and its 95% CI for reporting dementia are exemestane, 2.08 (1.35–3.19); anastrozole, 1.59 (1.09–2.32); and letrozole, 1.43 (1.05–1.95) and for Alzheimer's disease are exemestane, 0.94 (0.30–2.92); anastrozole: 2.63 (1.55–4.45); and letrozole, 1.33 (0.76–2.35). For senile dementia, only letrozole has cases, with an ROR of 6.77 (2.51–18.31). Signals of disproportionate reporting have been observed between the occurrence of dementia, dementia Alzheimer's type, and senile dementia with aromatase inhibitors, which is in line with estrogen functions and aromatase activity, as well as the findings from preclinical studies. Additional research is required to elucidate this intricate matter.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aromatase InhibitorsAlzheimer DiseaseDementiaHumansFemalePharmacovigilanceMiddle AgedAgedDatabases, FactualWorld Health OrganizationBreast NeoplasmsPostmenopauseAged, 80 and overAndrostadienes

Stichwörter der Autor:innen

Alzheimer's diseaseanastrozolearomatase inhibitorsdementiadisproportionality analysisexemestaneletrozolepharmacovigilance

Substanzen

Aromatase InhibitorsexemestaneAndrostadienes

Autor:innen und Institutionen

  • Department of Pharmacology, University of Murcia, Murcia, Spain.
  • Department of Cell Biology, Histology, Pharmacology and Genetics, Faculty of Medicine, Research Group Pharmacogenetics, Cancer Genetics, Genetic Polymorphisms and Pharmacoepidemiology, Centre for Research on Drug Safety…

ORCID-Profile: María Teresa Yuste, María Sainz-Gil, Elisa Escudero, Pedro Marín

Zitieren

APA

Yuste, M. T., Sainz-Gil, M., Escudero, E., & Marín, P. (2025). Dementia and Alzheimer's Disease Associated With Aromatase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database ( VigiBase ). Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70075

Vancouver

Yuste MT, Sainz-Gil M, Escudero E, Marín P. Dementia and Alzheimer's Disease Associated With Aromatase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database ( VigiBase ). Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70075

BibTeX
@article{Yuste2025,
  author = {Yuste, María Teresa and Sainz-Gil, María and Escudero, Elisa and Marín, Pedro},
  title = {Dementia and Alzheimer's Disease Associated With Aromatase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database ( VigiBase )},
  journal = {Pharmacology Research & Perspectives},
  year = {2025},
  doi = {10.1002/prp2.70075}
}
Kostenlos starten →